Patent 5965161 Issued on October 12, 1999. Estimated Expiration Date: October 12, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
424/457, Sustained or differential release424/456, Gelatin424/468, Sustained or differential release type424/484, Matrices424/486, Synthetic polymer424/487, Acrylic acid and derivatives424/488, Polysaccharides (e.g., cellulose, etc.)424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)514/772.3, Solid synthetic organic polymer514/772.6, Carboxylic acid containing monomer514/781, Cellulose or derivative514/783, Plant extract or plant material of undetermined constitution514/784Carboxylic acid or salt thereof
A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
Other References
Thomsen, L. Juul, "Utilizing melt pelletization tequnique for the preparation of prolonged release products", Pelletization, (material elaborated by assistant Prof. Lars Juul Thomsen, Dept. of Pharmaceutics, Royal Danish School of Pharmacy for the DIE course Pelletization Technology, Nov. 1992, 106 pages plus appendixes
Thomsen, L. Juul, "Prolonged Release Matrix Pellets by Melt Pelletization. Part IV: Drug Content, Drug Particle Size and Binder Composition", Pharmaceutical Technology Europa, pp. 19-22 (Oct. 1994)
N. Follonier et al., "Evaluation of Hot-Melt Extrusion as a New Technique for the Production of Polymer-Based Pellets for Sustained Release Capsules Containing High Loadings of Freely Soluble Drugs", Drug. Dev. and Industr. Pharm., vol. 20, No. 8, pp. 1323-1339, (1994)
Sustained Release Medications, pp. 50-53, Noyes Data Corp. (J.C. Johnson), 1980
M.A. Longer, "Sustained-Release Drug Deliver Systems", Remington's Pharm. Scie., 18th Edition, pp. 1676-1693, 1990
M. Zahirul I. Khan, "Recent Trends and Progress in Sustained or Controlled Oral Delivery of Some Water Soluble Drugs: Morphine Salts, Diltiazem and Captopril", Drug Devl. and Industr. Pharm., vol. 21, No. 9, pp. 1037-1070, 1995
Derwent Abstract of JP 62040277 (1987)
Derwent Abstract of JP 58109411 (1983)
Derwent Abstract of EP 358 107 (1990)
Derwent Abstract of DE 2553026 (1976)
R. Kinget, et al., "Preparation and Properties of Granulates Containing Solid Dispersions", Acta Phar. Tech., vol. 31, No. 2, 1985, pp. 57-62
M.J. Jozwiakowski et al., "Characterization of a Hot-Melt Fluid Bed Coating Process for Fine Granules", Pharm. Research, vol. 7, No. 11, 1990, pp. 1119-1124
M. Niskanen et al., "Pelletization in a Centrifugal Granulator, Part I: Effects of Binder-Solution Concentration", Pharm. Tech. Int'l., Oct. 1990, pp. 22-38
L. Lachman et al., "The Theory and Practice of Industrial Pharmacy", p. 315, Lea & Febiger, Phi. 1976
FDA Guide to Inspections of Oral Solid Dosage Forms Pre/Post Approval Issues for Development and Validation, Jan. 1994
T. Schaefer et al., "Melt Pelletization in a High Shear Mixer I Effects of Process Variables and Binder", Acta Pharm. Nord. vol. 4, No. 3, pp. 133-140, 1992
T. Schaefer et al., "Melt Pelletization in a High Shear Mixer II Power Consumption and Granule Growth", Acta Pharm. Nord. vol. 4, No. 3, pp. 141-148, 1992
T. Schaefer, et al., "Melt Granulation in a Laboratory Scale High Shear Mixer", Drug Dev. and Indust. Phar., vol. 16, No. 8, pp. 1249-1277, 1990
McTaggart, C.M. et al., "The Evaluation of Formulation and Processing Conditions of a Melt Granulation Process", Int'L.J. Pharm. vol. 19, No. 2, issued 1984, pp. 139-148
El-Shanawany, S., "Sustained Release of Nitrofurantion From Inert Wax Matrixes", J. Controlled Release, vol. 26, No. 1, issued 1993, pp. 11-19
P. Flanders, et al., "The Control of Drug Releases From Conventional Melt Granulation Matrices", Drug Dev. and Industrial Pharm., vol. 13, No. 6, pp. 1001-1022, 1987
Thomsen, L. Juul, "Matrix Pellets Prolonged Formulations Prepared by Melt Pelletization", Dept. of Pharm. Royal Danish School of Pharmacy, 1992
Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables", Drug Development and Industrial Pharmac y, vol. 19, No. 15, pp. 1867-1887 (1993)
Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders", Drug Development and Industrial Pharmacy, vol. 20, No. 7, pp. 1179-1197 (1994)
J.P. Skelly, Scael-up of Immediate Releae Oral Solid Dosage Forms, AAPS/FDA Workshop Committee, Pharmaceutical Technology, pp. 68-74, Apr. 1995
SK Baveja et al., Int. J. Pharmaceutics, 41, (1988), pp. 55-62
Formulating for Controlled Release with METHOCEL.RTM. Premium Cellulose Ethers, The Dow Chemical Company, 1989
M.S. Vasquez et al., Ddrug Dev. & Ind. Pharmacy, 18 (11 & 12), pp. 1355-1378 (1992)
L W S Cheong et al., Pharm. Res. 9 (11), pp. 1510-1514 (1992)
Hunt et al., Clin. Ther., vol. 13, No. 4, pp. 482-488, 1990
DA Alderman, Int. J. Pharm. Tech. and Prod. Mfr., 5(3), pp. 1-9, 1984
HE Huber et al., J. Pharm. Sci. 55 (9), Sep. 1966, pp. 974-976
Lin SY et al., Current Therapeutic Research 52 (3), pp. 486-492, Sep., 1992
Aqualon Technical Information Bulletin, VC-585, 1991
P. Colombo, Advanced Drug Delivery Reviews, 11 (1993), pp. 37-57
KV Ranga Rao et al., Int. J. Pharmaceutics, 48 (1988), pp. 1-13
JE Hogan, Drug Dev. & Ind. Pharmacy, 15 (6 & 7), p. 975-999, (1989)
JL Ford et al., Int. J. Pharmaceutics, 24 (1985), pp. 327-338
PB Daly et al., Int. J. Pharmaceutics, 18 (1984), pp. 201-205
E.M.G. van Bommel, "Production and Evaluation of In Vitro Release Characteristics of Spherical Grandient Matrix Systems", Acta Phar., Technol. 3b (2), pp. 74-78, 1990
Nicolas Follonier et al., "Various Ways of Modulating the Release of Diltiazem Hydrochloride from Hot-melt Extruded Sustained Release Pellets Prepard Using Polymeric Materials", Journal of Controlled Release, 36, pp. 243-250 (1995)
Alan Royce et al., "Alternative Granulation Technique: Melt Granulation", Drug Development and Industrial Pharmacy, 22 (9 & 10), pp. 917-992 (1996)
Sekiguchi, et al., "Studies on Absorption of Eutectic Mixture . . . ", Chem. Pharm. Bull., vol. 9 (1961), pp. 866-872
A.R. Gennaro, "Particle Phenomena and Coarse Dispersions", Remington's Pharmaceutical Sciences, 17th Edition, 1985, p. 301
J.L. Ford, "The Current Status of Solid Dispersions", Pharm. Acta Helv. 61, Nr. 3 (1986), pp. 69-88
CA 74:67660 (1996) (1 page)
CA 101:60081 (1996) (1 page)
CA 113:98975 (1996) (1 page)
CA 113:218240 (1996) (1 page)
CA 114:30199 (1996) (1 page)
CA 112:75438 (1996) (1 page)
CA 115:177364 (1997) (1 page)
Frank W. Goodhart et al., Design and Use of a Laboratory Extruder for Pharmaceutical Granulations, Journal of Pharm. Scien., 62(1), p. 133-136 (Jan. 1973)
Follonier, Nicolas, et al., "Hot-Melt Extruded Pellets For The Sustained Release Of Highly Dosed Freely Soluble Drugs", Capsule News, vol. 1, No. 3, Edited by Roland Daumesnil, (Jun./Jul. 1991)
Nicolas Follonier1, Eric Doelker and Ewart T. Cole, Evaluation of Hot-Melt Extrusion as a New Technique for the Production of Polymer-Based Pellets for Sustained Release Capsules containing high loadings of freely soluble drugs, Drug Development and Industrial Pharmacy, 20(8), 1323-1339 (1994)
Nicolas Follonier1, Eric Doelker1 and Ewart T. Cole2, Hot-Melt Extruded Pellets for the Sustained Release of Highly Dosed Freely Solluble Drugs, Proceed. Intern. Symp. COntrol. Rel. Bioact. Mater., 18(1991), pp. 578-579
Twin Screw Extrusion in the Production of Novel Dosage Forms, Pharmaceutical Manufacturing Review (Jun. 1994
October 12, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
